Menu
Search
|

Menu

Close
X

Cumberland Pharmaceuticals Inc CPIX.OQ (NASDAQ Stock Exchange Global Select Market)

6.95 USD
+0.02 (+0.29%)
As of Feb 16
chart
Previous Close 6.93
Open 6.98
Volume 1,382
3m Avg Volume 3,934
Today’s High 7.00
Today’s Low 6.95
52 Week High 7.95
52 Week Low 5.30
Shares Outstanding (mil) 15.75
Market Capitalization (mil) 109.45
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
18
FY16
33
FY15
34
EPS (USD)
FY17
-0.402
FY16
-0.058
FY15
0.043
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
2.84
8.57
Price to Book (MRQ)
vs sector
1.68
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
12.29
15.12
LT Debt to Equity (MRQ)
vs sector
12.29
11.85
Return on Investment (TTM)
vs sector
-10.37
13.54
Return on Equity (TTM)
vs sector
-11.36
14.80

EXECUTIVE LEADERSHIP

A. Kazimi
Chairman of the Board, Principal Executive Officer, Since 2016
Salary: $450,000.00
Bonus: $200,000.00
Michael Bonner
Senior Director Finance and Accounting and Chief Financial Officer, Since 2016
Salary: --
Bonus: --
Martin Cearnal
Senior Vice President, Chief Commercial Officer, Director, Since 2008
Salary: $249,500.00
Bonus: $80,000.00
Leo Pavliv
Senior Vice President - Operations, Chief Development Officer, Since 2012
Salary: $326,750.00
Bonus: $80,000.00
James Herman
Vice President - National Accounts, Chief Compliance Officer, Since 2011
Salary: $199,250.00
Bonus: $40,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

2525 W End Ave Ste 950
NASHVILLE   TN   37203-1608

Phone: +1615.2550068

Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease (AERD).

SPONSORED STORIES